Merck spinout grabs some assets and launches a quest for the Holy Grail in antibiotics R&D
Terry Roemer did a lot more than clean out his desk when he decided to leave Merck after a 13-year career developing antibodies at the pharma giant. With R&D chief Roger Perlmutter’s blessings, he also gathered some preclinical programs to take with him that now form the pipeline at his new, upstart biotech based in Union, New Jersey. And he’s working with a small team of ex-Merck scientists ready to get things moving toward the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.